))
Dermatology Edition: Top Headlines for Week of October 16, 2023
Manage episode 407442253 series 3560281
Content provided by Healio. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Healio or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this edition, FDA issues complete response letter for relabotulinumtoxinA; mucocutaneous manifestations may signal COVID-induced inflammatory disease in children and more. Read the full coverage here:
FDA issues complete response letter for relabotulinumtoxinA for frown lines, crow’s feet
Mucocutaneous manifestations may signal COVID-induced inflammatory disease in children
FDA approves Zoryve for pediatric psoriasis
Colloidal oatmeal, prescription cream comparable in Black children with atopic dermatitis
FDA issues complete response letter for lebrikizumab for eczema treatment
References:
Imam B. Mucocutaneous clinical manifestation of multi-system inflammatory syndrome in children (MIS-C). Presented at: Skin of Color Update; Oct. 6-8, 2023; New York.
Lisante TA, et al. J Dermatolog Treat. 2023;doi:10.1080/09546634.2023.2241587.
117 episodes
Share
